Alendronic Acid
A bisphosphonate drug that attaches to bone mineral and blocks the activity of osteoclasts, the cells responsible for breaking down bone tissue, thereby maintaining or increasing bone density. It is prescribed for osteoporosis, Paget's disease, and bone complications from certain cancers, reducing fracture risk with weekly or monthly dosing.
Peso molecular
249,1000 g/mol
LogP
-6,50
TPSA
161,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Estructura 2D
Cite this structure
Embed this structure
SMILES
NCCCC(O)(P(=O)(O)O)P(=O)(O)O
InChI
InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
Molecular Formula
C4H13NO7P2
HBD / HBA
6 / 8
Enlaces Rotables
5
Átomos Pesados
14
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A bisphosphonate drug that attaches to bone mineral and blocks the activity of osteoclasts, the cells responsible for breaking down bone tissue, thereby maintaining or increasing bone density. It is prescribed for osteoporosis, Paget's disease, and bone complications from certain cancers, reducing fracture risk with weekly or monthly dosing.
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Yes, Alendronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL870. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2088. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alendronic-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alendronic-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alendronic-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alendronic-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alendronic-acid"></drugfyi-drug>